Reuters logo
BRIEF-Novan acquires IP rights to treat viral malignancies with nitric oxide
2017年10月18日 / 上午11点24分 / 1 个月前

BRIEF-Novan acquires IP rights to treat viral malignancies with nitric oxide

Oct 18 (Reuters) - Novan Inc

* Novan acquires IP rights to treat viral malignancies with nitric oxide

* Novan Inc- ‍ Has initiated clinical development of company’s nitric oxide platform in field of immunology​

* Novan Inc- ‍Top line results for phase 1b trial of co’s nitric oxide platform​ are expected in Q2 of 2018

* Novan Inc- ‍Targeting to begin phase 1b trial with SB414 in adults with atopic dermatitis before year end with top line results expected in Q3 of 2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below